How Long Can Stomach Cancer Patients Survive? A 2026 Look at the Numbers

For people diagnosed with stomach cancer in Korea, the 5-year relative survival rate is 78.6% (National Cancer Registration Statistics, 2019–2023). This figure represents "the probability of being alive after 5 years" at a population level — it is not a promise about how long any individual person will live.

Key Takeaways

• Korea's 5-year relative survival rate for stomach cancer is 78.6% (National Cancer Registration Statistics 2019–2023, National Cancer Center Korea's Central Cancer Registry).
• Over the same period, the 5-year relative survival rate for all cancers combined in Korea is 73.7%, meaning stomach cancer outcomes are somewhat better than the overall average.
• According to the U.S. SEER database (2016–2022), the 5-year relative survival rate for stomach cancer is 39.8%. Both figures are nationwide statistics, not results from any single hospital.
• Much of the gap comes down to how early the cancer is caught — Korea runs a national screening program offering gastric endoscopy every two years starting at age 40.
• Actual survival time varies widely between individuals depending on stage, tumor type, age, and other existing health conditions.

What Exactly Does the '5-Year Relative Survival Rate' Mean?

• The 5-year relative survival rate compares the proportion of a group of cancer patients still alive after 5 years to the survival of the general population of the same age and sex. It is a population-level statistic, not a prediction of how many years any one person will live.
• Per the National Cancer Registration Statistics 2019–2023, Korea's 5-year relative survival rate for stomach cancer is 78.6%. This nationwide figure is compiled by the National Cancer Center Korea's Central Cancer Registry from cancer registry data across the country — it does not reflect the treatment outcomes of any particular hospital.
• During the same period, the U.S. SEER figure for stomach cancer was 39.8% — a large gap on a simple comparison. However, this difference isn't due to treatment technology alone; how early the cancer is caught plays a major role. Korea's national screening program means a relatively high share of stomach cancers are caught at an early stage.

How Do Survival and Treatment Direction Change by Stage?

• Stomach cancer's treatment goals shift fundamentally depending on stage, which is the single biggest factor affecting survival outlook. Staging uses the TNM system, combining T (depth of invasion into the stomach wall), N (lymph node involvement), and M (distant metastasis).
• Stage 1 cancer remains confined to the shallow layers of the stomach wall with little or no lymph node involvement. For early-stage disease, endoscopic submucosal dissection alone is often sufficient — no surgical removal of the stomach is needed, so eating and daily life are largely preserved.
• Stage 2–3 cancer has invaded more deeply into the stomach wall or spread to lymph nodes. Treatment commonly involves subtotal or total gastrectomy combined with lymph node dissection, often paired with adjuvant chemotherapy before or after surgery.
• Stage 4 (distant metastasis) shifts the treatment goal from cure to disease control. Systemic chemotherapy becomes the core treatment, with targeted therapies or immune checkpoint inhibitors added depending on biomarker test results such as HER2, PD-L1, and CLDN18.2.
• Even though all three groups fall under the label 'stomach cancer,' treatment approach and outlook differ completely between them — which is why accurate staging is the essential first step before discussing survival outlook.

How Does Follow-Up Surveillance Work After Treatment?

• After treatment ends, patients undergo repeated checkups, blood tests, CT scans, and gastric endoscopy at set intervals. Typically, the first 2–3 years involve closer monitoring, with intervals gradually extending out to the 5-year mark; the exact schedule depends on stage and treatment type.
• For patients who underwent endoscopic resection, endoscopy intervals are especially important to check for new lesions in the remaining stomach tissue. After gastrectomy, nutritional status along with vitamin and iron levels are also monitored.
• For patients returning to their home country after treatment, a handover document listing the schedule and items for the next tests allows local medical staff to take over follow-up monitoring.

FAQ — Whose Treatment Results Do the Survival Rate Numbers Reflect?

They reflect nationwide statistics for Korea as a whole, not any specific hospital (National Cancer Registration Statistics 2019–2023). Under Korean medical law, individual hospitals' treatment outcomes cannot be used in advertising, and actual treatment results vary by individual depending on stage and overall health condition.

FAQ — Does Stage 4 Stomach Cancer Mean Giving Up on Treatment?

No. Even at stage 4, the treatment goal simply shifts from cure to control, with systemic chemotherapy continuing as the core treatment. Standard approaches now include adding targeted therapy for HER2-positive cases and immune checkpoint inhibitors for cases with high PD-L1 expression, alongside chemotherapy. Radiation therapy may also be selectively used to manage bleeding or pain. The specific direction is determined by the treating medical team based on biomarker test results and the patient's overall condition.

Sources and Notes

• This article was written based on the National Cancer Registration Statistics 2019–2023 (National Cancer Center Korea's Central Cancer Registry), U.S. SEER statistics 2016–2022, and general information at the level of the National Cancer Information Center and NCCN patient guidelines.
• This content is intended for general medical information purposes only. Diagnosis, treatment approach, and outcomes may vary depending on individual circumstances. Please consult directly with a medical professional to determine accurate diagnosis and treatment.